IOB - Delayed Quote EUR

Poxel S.A. (0RA2.IL)

0.3925

-0.0100

(-2.48%)

At close: May 2 at 5:21:16 PM GMT+1

Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results

LYON, France, April 16, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its cash position as of March 31, 2025, provided an update on its financial situation and ongoing negotiations with its creditors, and announced the postponement

Business Wire 17 days ago

PXXLF
Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment

LYON, France, April 08, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG® package insert for patients with renal impairment with

Business Wire 25 days ago

PXXLF
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment

LYON, France, March 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that the Japanese Patent Office has granted Poxel a new patent (n°7635474) covering the use of Imeglimin in type-2 diabetic patients with moderate to severe ren

Business Wire last month

PXXLF
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

LYON, France, March 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the positive top-line results for PXL065 from a preclinical study conducted in a mouse model of hypertrophic cardiomyopathy. PXL065 is a novel, proprietary deut

Business Wire last month

PXXLF
Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook

LYON, France, February 19, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports its full-year revenue for the period ended December 31, 2024 and provides an update on its financial situation and outlook, in particular following the non-ado

Business Wire 2 months ago

PXXLF
Poxel Announces Results of its Combined General Meeting Held on February 11, 2025

LYON, France, February 11, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that it held its Combined General Meeting on February 11, 2025, at 9;00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdu

Business Wire 2 months ago

PXXLF
Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

LYON, France, January 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports TWYMEEG® gross sales in Japan for Q4 2024 and sales forecast shared by its partner Sumitomo Pharma as part of its Q3 FY2024 financial results1.

Business Wire 2 months ago

PXXLF
Poxel Announces its Financial Calendar for 2025

LYON, France, January 23, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2025.

Business Wire 3 months ago

PXXLF
Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

LYON, France, January 21, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that a Combined General Meeting will be held on February 11, 2025, at 9:00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at

Business Wire 3 months ago

PXXLF
Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that China's National Intellectual Property Administration ("CNIPA") has granted Poxel patent ZL201980015603.X for Imeglimin, a first-in-class drug targeting

Business Wire 3 months ago

PXXLF
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

LYON, France, January 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced that net sales of TWYMEEG® in Japan reached JPY 5 billion (EUR 30.6 million2) in Sumitomo Pharma's fiscal year 2024, making Poxel eligible for positive net ro

Business Wire 3 months ago

PXXLF
Availability of Poxel’s 2024 Half-Year Financial Report

LYON, France, December 23, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2024.

Business Wire 4 months ago

PXXLF
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

LYON, France, December 09, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces its half-year financial results for the period ended June 30, 2024 and provides an update on its financial situation and outlook, in particular following the

Business Wire 4 months ago

PXXLF
Poxel Announces Results from November 28, 2024 Annual General Meeting

LYON, France, November 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that it held its Annual General Meeting on November 28, 2024, at 9;00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdun-

Business Wire 5 months ago

PXXLF
Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

LYON, France, November 07, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that the Annual General Meeting (AGM) will be held on November 28, 2024, at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cour

Business Wire 5 months ago

PXXLF
Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

LYON, France, November 06, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2024.

Business Wire 5 months ago

PXXLF
Poxel Announces Availability of the 2023 Universal Registration Document

LYON, France, October 11, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2023, has been filed with the French market authority (Autorité des Marchés F

Business Wire 6 months ago

PXXLF
Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

Poxel SA navigates financial restructuring and strategic partnerships amid increased net losses and reduced cash reserves.

GuruFocus.com 6 months ago

POXEL.PA
Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

LYON, France, October 03, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (MASH2) and rare metabolic disorders, today announced its results for the year ended December 31, 2023, and provided a corporate update.

Business Wire 6 months ago

PXXLF
Poxel Announces its Financial Calendar for 2024

LYON, France, October 01, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.

Business Wire 6 months ago

PXXLF

Performance Overview

Return	0RA2.IL	CAC 40 (^FCHI)
YTD	+189.88%	+5.28%
1-Year	-36.33%	-1.82%
3-Year	-81.05%	+20.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Poxel S.A. (0RA2.IL)

Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results

Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment

Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment

Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy

Poxel Reports Revenue for the Full Year 2024 and Provides an Update on its Financial Position and Outlook

Poxel Announces Results of its Combined General Meeting Held on February 11, 2025

Poxel’s partner Sumitomo Pharma reports TWYMEEG® gross sales in Japan for Q4 2024 and FY 2024 sales forecast

Poxel Announces its Financial Calendar for 2025

Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan

Availability of Poxel’s 2024 Half-Year Financial Report

Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook

Poxel Announces Results from November 28, 2024 Annual General Meeting

Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents

Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update

Poxel Announces Availability of the 2023 Universal Registration Document

Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges

Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update

Poxel Announces its Financial Calendar for 2024

Performance Overview